Technology
Health
Pharmaceutical

Genprex

$1.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.49%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Genprex and other stocks, options, ETFs, and crypto commission-free!

About

Genprex, Inc. Common Stock, also called Genprex, is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. Read More It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Employees
Headquarters
Austin, Texas
Founded
2009
Market Cap
27.00M
Price-Earnings Ratio
Dividend Yield
Average Volume
120.06K
High Today
$1.85
Low Today
$1.79
Open Price
$1.83
Volume
3.49K
52 Week High
$19.45
52 Week Low
$0.95

Collections

Technology
Health
Pharmaceutical
Therapy
Cancer Prevention
Medical
2018 IPO
US

News

Associated PressMar 15

NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy

NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc.

164
Associated PressMar 14

NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring clinical-stage gene therap...

187
PR NewswireMar 12

Making Profits, Saving Lives With Gene Therapy

NEW YORK, March 12, 2019 /PRNewswire/ -- After thirty years of development, gene therapy is seeing a surge of progress and profitability.

106

Earnings

Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 26, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.